Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sunesis Pharmaceutic (SNSS)

Sunesis Pharmaceutic (SNSS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 96,255
  • Shares Outstanding, K 18,093
  • Annual Sales, $ 2,070 K
  • Annual Income, $ -23,330 K
  • 60-Month Beta 2.21
  • Price/Sales 29.96
  • Price/Cash Flow N/A
  • Price/Book 5.09
Trade SNSS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.39
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/09/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility N/A
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +42.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +126.38%
on 01/28/21
7.09 -24.93%
on 02/24/21
+2.29 (+75.58%)
since 01/22/21
3-Month
1.33 +300.00%
on 11/25/20
7.09 -24.93%
on 02/24/21
+3.96 (+291.18%)
since 11/24/20
52-Week
1.12 +375.00%
on 11/06/20
11.30 -52.92%
on 02/26/20
-3.88 (-42.17%)
since 02/24/20

Most Recent Stories

More News
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

SNSS : 18.62 (+24.30%)
LOAC : 13.45 (+1.89%)
FBSS : 21.28 (+0.47%)
CPAH : 3.48 (+0.43%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of UROV, SNSS, TCF, and PS Mergers

WILMINGTON, Del., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

UROV : 16.24 (+0.06%)
SNSS : 18.62 (+24.30%)
TCF : 45.18 (-3.28%)
PS : 22.45 (+0.13%)
SUNESIS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS:...

SNSS : 18.62 (+24.30%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of INFO, SNSS, INSU, and FBSS Mergers

WILMINGTON, Del., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

INFO : 108.61 (+0.74%)
SNSS : 18.62 (+24.30%)
FBSS : 21.28 (+0.47%)
INAQ : 9.79 (unch)
INVESTIGATION ALERT: Halper Sadeh LLP Continues to Investigate the Following Companies; Shareholders are Encouraged to Contact the Firm – SNSS, WORK, WDR, ANH

NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

SNSS : 18.62 (+24.30%)
WORK : 45.20 (+0.09%)
WDR : 24.98 (-0.04%)
ANH : 2.98 (+0.34%)
ALERT: Halper Sadeh LLP Encourages INFO, SNSS, and WORK Shareholders to Contact the Firm

NEW YORK, NY / ACCESSWIRE / December 5, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following mergers: IHS Markit Ltd. (NYSE:INFO) concerning potential...

SNSS : 18.62 (+24.30%)
INFO : 108.61 (+0.74%)
WORK : 45.20 (+0.09%)
SUNESIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sunesis Pharmaceuticals, Inc. - SNSS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS:...

SNSS : 18.62 (+24.30%)
Lifshitz Law Firm, P.C. Announces Investigation of CLCT, FBM, SNSS and WORK

NEW YORK, NY / ACCESSWIRE / December 3, 2020 / Collectors Universe, Inc. (NASDAQ:CLCT) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale...

CLCT : 91.92 (+0.04%)
FBM : 19.24 (unch)
SNSS : 18.62 (+24.30%)
WORK : 45.20 (+0.09%)
Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm – GV, CLCT, SNSS, WORK

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating:

GV : 7.00 (unch)
CLCT : 91.92 (+0.04%)
SNSS : 18.62 (+24.30%)
WORK : 45.20 (+0.09%)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Sunesis Pharmaceuticals, Inc. Merger

WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Sunesis Pharmaceuticals, Inc. (“Sunesis”) (NASDAQ CM: SNSS ) regarding possible breaches...

SNSS : 18.62 (+24.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing...

See More

Key Turning Points

3rd Resistance Point 9.13
2nd Resistance Point 8.11
1st Resistance Point 6.71
Last Price 18.62
1st Support Level 4.30
2nd Support Level 3.28
3rd Support Level 1.88

See More

Last Price 18.62
52-Week High 11.30
Fibonacci 61.8% 7.41
Fibonacci 50% 6.21
Fibonacci 38.2% 5.01
52-Week Low 1.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar